Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals (Nasdaq: APLS) has announced the approval of equity inducement awards for one new employee, granted on January 2, 2025. The awards, consisting of 4,135 restricted stock units (RSUs), were granted outside the company's 2017 Stock Incentive Plan but under the 2020 Inducement Stock Incentive Plan. The RSUs will vest over four years, with 25% vesting on the first anniversary of the grant date and an additional 25% annually thereafter, contingent on continued employment. The grants were approved in compliance with Nasdaq Listing Rule 5635(c)(4).
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato l'approvazione di premi in azioni per un nuovo dipendente, concessi il 2 gennaio 2025. I premi, consistenti in 4.135 unità azionarie restrittive (RSUs), sono stati concessi al di fuori del Piano di Incentivi Azionari del 2017 dell'azienda, ma sotto il Piano di Incentivi Azionari del 2020. Le RSUs matureranno nell'arco di quattro anni, con il 25% che matura al primo anniversario della data di concessione e un ulteriore 25% annualmente da quel momento in poi, a condizione di continuare l'impiego. I premi sono stati approvati in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado la aprobación de premios en acciones para un nuevo empleado, otorgados el 2 de enero de 2025. Los premios, que constan de 4,135 unidades de acciones restringidas (RSUs), se otorgaron fuera del Plan de Incentivos de Acciones de 2017 de la empresa, pero bajo el Plan de Incentivos de Acciones de Inducción de 2020. Las RSUs se irán consolidando durante cuatro años, con un 25% consolidándose en el primer aniversario de la fecha de concesión y un adicional del 25% anualmente en adelante, condicionado a la continuación del empleo. Las concesiones fueron aprobadas en cumplimiento de la Regla de Cotización Nasdaq 5635(c)(4).
Apellis Pharmaceuticals (Nasdaq: APLS)는 2025년 1월 2일에 새로운 직원에게 주식 보상 수여가 승인되었다고 발표했습니다. 이 상 여는 4,135개의 제한된 주식 단위(RSUs)로 구성되며, 회사의 2017년 주식 인센티브 계획 외부에서, 그러나 2020년 유도 주식 인센티브 계획 하에 수여되었습니다. RSU는 4년에 걸쳐 취득되며, 첫 해 기념일에 25%가 취득되고 이후 매년 추가로 25%가 취득됩니다. 이는 계속 고용 조건에 따라 달라집니다. 이 상여는 나스닥 상장 규칙 5635(c)(4)을 준수하여 승인되었습니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé l'approbation de récompenses en actions pour un nouvel employé, accordées le 2 janvier 2025. Les récompenses, composées de 4 135 unités d'actions restreintes (RSUs), ont été accordées en dehors du Plan d'Incitation aux Actions de 2017 de l'entreprise, mais dans le cadre du Plan d'Incitation aux Actions de 2020. Les RSUs s'acquerront sur une période de quatre ans, avec 25 % acquis à la première anniversaire de la date d'attribution, et un supplément de 25 % chaque année par la suite, sous condition d'emploi continu. Les attributions ont été approuvées conformément à la Règle de cotation Nasdaq 5635(c)(4).
Apellis Pharmaceuticals (Nasdaq: APLS) hat die Genehmigung von Aktienvergütungen für einen neuen Mitarbeiter bekannt gegeben, die am 2. Januar 2025 gewährt wurden. Die Vergütungen, bestehend aus 4.135 beschränkten Aktieneinheiten (RSUs), wurden außerhalb des Aktienanreizplans des Unternehmens von 2017, jedoch im Rahmen des Plans für Aktienanreize von 2020 gewährt. Die RSUs verfallen über vier Jahre, wobei 25% am ersten Jahrestag des Gewährungstags und anschließend jährlich weitere 25% unter der Bedingung, dass die Beschäftigung fortgesetzt wird, verfallen. Die Vergaben wurden in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received 4,135 restricted stock units (RSUs). Each RSU will vest as to
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Tracy Vineis
media@apellis.com
617-420-4839
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
How many RSUs did Apellis Pharmaceuticals (APLS) grant in their January 2025 inducement award?
What is the vesting schedule for APLS's January 2025 inducement RSU grants?
Under which plan were the January 2025 APLS inducement grants issued?
What Nasdaq rule did Apellis Pharmaceuticals comply with for their January 2025 inducement grants?
